CSIMarket
 


Royalty Pharma Plc  (RPRX)
Other Ticker:  
 
 

RPRX's Operating Income Growth by Quarter and Year

Royalty Pharma Plc's Operating Income results by quarter and year




RPRX Operating Income (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 612.90 -482.66 153.42 677.40
III Quarter September 151.44 192.21 303.05 510.57
II Quarter June 248.84 377.79 744.95 409.35
I Quarter March 478.97 219.72 229.30 -1.91
FY   1,492.15 307.06 1,430.72 1,595.41



RPRX Operating Income fourth quarter 2023 Y/Y Growth Comment
Royalty Pharma Plc in the fourth quarter 2023 achieved Operating Income of $ 612.90 millions compare to Operating Loss recorded in same quarter a year ago.

Looking into fourth quarter 2023 results within Major Pharmaceutical Preparations industry 20 other companies have achieved higher Operating Income growth. While Royalty Pharma Plc' s Operating Income no change of % ranks overall at the positon no. 871 in the fourth quarter 2023.

Explain Operating Income growth


RPRX Operating Income ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - -77.35 % -
III Quarter September -21.21 % -36.57 % -40.64 % -
II Quarter June -34.13 % -49.29 % 81.98 % -
I Quarter March 117.99 % -4.18 % - -
FY   385.95 % -78.54 % -10.32 % -

Financial Statements
Royalty Pharma Plc's fourth quarter 2023 Operating Income $ 612.90 millions RPRX's Income Statement
Royalty Pharma Plc's fourth quarter 2022 Operating Income $ -482.66 millions Quarterly RPRX's Income Statement
New: More RPRX's historic Operating Income Growth >>


RPRX Operating Income (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December 304.71 % - -49.37 % 32.68 %
III Quarter September -39.14 % -49.12 % -59.32 % 24.73 %
II Quarter June -48.05 % 71.94 % 224.88 % -
I Quarter March - 43.21 % -66.15 % -
FY (Year on Year)   385.95 % -78.54 % -10.32 % -




Operating Income fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #21
Healthcare Sector #69
Overall #871

Operating Income Y/Y Growth Statistics
High Average Low
441.46 % 50.02 % -78.54 %
(Jun 30 2021)   (Dec 31 2022)
Operating Income fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #21
Healthcare Sector #69
Overall #871
Operating Income Y/Y Growth Statistics
High Average Low
441.46 % 50.02 % -78.54 %
(Jun 30 2021)   (Dec 31 2022)

Operating Income by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Royalty Pharma Plc's Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
304.71 % 32.58 % -66.15 %
(Dec 31 2023)  


RPRX's IV. Quarter Q/Q Operating Income Comment
Royalty Pharma Plc achieved in the IV. Quarter 2023 above company average sequential Operating Income doubling of 304.71%, to $ 612.90 millions, from $151.44 millions in the third quarter.
Royalty Pharma Plc is impressively improving, not just recording higher then normal gain, and additionally accelerating speed, Dahnya López , Major Pharmaceutical Preparations industry expert added.

Within Major Pharmaceutical Preparations industry Royalty Pharma Plc achieved highest sequential Operating Income growth. While Royalty Pharma Plc's Operating Income growth quarter on quarter, overall rank is 56.


Operating Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #1
Healthcare Sector #3
Overall #56
Operating Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #1
Healthcare Sector #3
Overall #56
Operating Income Q/Q Growth Statistics
High Average Low
304.71 % 32.58 % -66.15 %
(Dec 31 2023)  


RPRX's IV. Quarter Q/Q Operating Income Comment
Royalty Pharma Plc achieved in the IV. Quarter 2023 above company average sequential Operating Income doubling of 304.71%, to $ 612.90 millions, from $151.44 millions in the third quarter.
Royalty Pharma Plc is going from strength to strength, not just recording higher then normal growth, and additionally accelerating rate, Dahnya López , Major Pharmaceutical Preparations industry expert said.

Within Major Pharmaceutical Preparations industry Royalty Pharma Plc achieved highest sequential Operating Income growth. While Royalty Pharma Plc's Operating Income growth quarter on quarter, overall rank is 56.


Royalty Pharma Plc's 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Operating Income 12 Months Ending $ 1,492.15 $ 396.60 $ 437.37 $ 566.32 $ 307.07
Y / Y Operating Income Growth (TTM) 385.94 % -57.95 % -58.5 % -60.15 % -78.54 %
Year on Year Operating Income Growth Overall Ranking # 890 # 1832 # 1837 # 1618 # 1555
Seqeuential Operating Income Change (TTM) 276.24 % -9.32 % -22.77 % 84.43 % -67.44 %
Seq. Operating Income Growth (TTM) Overall Ranking # 871 # 1281 # 1603 # 1224 # 1775




Cumulative Operating Income growth Comment
Royalty Pharma Plc saw improvement in Operating Income growth trend, posting cumulative 12 months Operating Income growth of 385.94% year on year, to $ 1,492 millions if the fiscal year would have ended in Dec 31 2023.
Royalty Pharma Plc's trailing twelve months Operating Income growth was higher than company's average 50.02% and higher than -57.95% growth in Sep 30 2023.
But from twelve months ended Sep 30 2023 rise was less at 276.24 % from $396.6 millions recorded in twelve months ending a quarter Sep 30 2023 Dahnya López  added on.
Yet it was confirmation of strength, as the average Q/Q TTM Operating Income growth is at 50.02%.
The growth was even higher from the previous reporting period clinched at 276.24 % increase from $396.6 millions in twelve months ending a quarter before.

In the Healthcare sector 68 other companies have achieved higher trailing twelve month Operating Income growth. While Total ranking has impoved so far to 890, from total ranking in previous quarter at 1832.

Operating Income TTM Q/Q Growth Statistics
High Average Low
441.46 %
50.02 %
-78.54 %
 

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 21
Healthcare Sector # 69
Overall # 890

Operating Income TTM Y/Y Growth Statistics
High Average Low
441.46 %
50.02 %
-78.54 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 21
Sector # 69
S&P 500 # 871
Cumulative Operating Income growth Comment
Royalty Pharma Plc saw improvement in Operating Income growth trend, posting cumulative 12 months Operating Income growth of 385.94% year on year, to $ 1,492 millions if the fiscal year would have ended in Dec 31 2023.
Royalty Pharma Plc's trailing twelve months Operating Income growth was higher than company's average 50.02% and higher than -57.95% growth in Sep 30 2023.
But sequential rise was beneth at 276.24 % from $396.6 millions recorded in the period from Sep 30 2023 to Dec 31 2022 Dahnya López  went on.
Still this was validation of strength, as the typical sequential gain stands at 50.02%.
The growth was even stronger from the previous reporting period clinched at 276.24 % rise from $396.6 millions in twelve months ending a quarter Sep 30 2023.

In the Healthcare sector 68 other companies have achieved higher trailing twelve month Operating Income growth. While Total ranking has impoved so far to 890, from total ranking in previous quarter at 1832.

Operating Income TTM Q/Q Growth Statistics
High Average Low
441.46 %
50.02 %
-78.54 %
 


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 21
Healthcare Sector # 69
Overall # 890

Operating Income TTM Y/Y Growth Statistics
High Average Low
441.46 %
50.02 %
-78.54 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 21
Sector # 69
S&P 500 # 871




Other Operating Income Growth
Major Pharmaceutical Preparations Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
RPRX's Operating Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for RPRX's Competitors
Operating Income Growth for Royalty Pharma Plc's Suppliers
Operating Income Growth for RPRX's Customers

You may also want to know
RPRX's Annual Growth Rates RPRX's Profitability Ratios RPRX's Asset Turnover Ratio RPRX's Dividend Growth
RPRX's Roe RPRX's Valuation Ratios RPRX's Financial Strength Ratios RPRX's Dividend Payout Ratio
RPRX's Roa RPRX's Inventory Turnover Ratio RPRX's Growth Rates RPRX's Dividend Comparisons



Companies with similar Operating Income doubling for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Dec 31 2023
Cadre Holdings Inc -0.36%$ -0.362 millions
Prestige Consumer Healthcare Inc -0.40%$ -0.404 millions
Phibro Animal Health Corporation-0.90%$ -0.903 millions
Inmode Ltd -1.11%$ -1.109 millions
Resmed Inc -1.82%$ -1.820 millions
Essa Pharma inc -3.45%$ -3.446 millions
Bausch and Lomb Corp-3.92%$ -3.922 millions
National Research Corporation-4.35%$ -4.346 millions
Vertex Pharmaceuticals Inc-4.35%$ -4.354 millions
Fresenius Medical Care Ag-9.41%$ -9.414 millions
Edwards Lifesciences Corporation-10.65%$ -10.652 millions
Regeneron Pharmaceuticals Inc -15.16%$ -15.164 millions
Harmony Biosciences Holdings inc -15.58%$ -15.578 millions
Charles River Laboratories International inc -18.86%$ -18.856 millions
Biogen Inc -19.42%$ -19.417 millions
Mettler toledo International Inc -19.91%$ -19.915 millions
Bristol myers Squibb Company-20.65%$ -20.646 millions
Qiagen N v -22.87%$ -22.866 millions
Baxter International Inc -22.95%$ -22.946 millions
Artivion Inc -23.20%$ -23.196 millions
Bio rad Laboratories Inc -24.46%$ -24.460 millions
Hologic Inc-24.47%$ -24.466 millions
Becton Dickinson And Company-24.96%$ -24.957 millions
Mesoblast Ltd-25.69%$ -25.686 millions
Sanofi-26.10%$ -26.098 millions
Amedisys Inc -26.45%$ -26.448 millions
Avantor Inc -27.20%$ -27.204 millions
Gilead Sciences Inc -28.89%$ -28.893 millions
Semler Scientific Inc -30.28%$ -30.282 millions
Pro dex Inc -31.66%$ -31.662 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com